# Lubka T Roumenina

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 118 papers | 9,366 citations | 61857 43 h-index | 40881 93 g-index |
| 131 all docs | 131 docs citations | 131 times ranked | 8749 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Complement System Part I Ã¢â‚¬â€œ Molecular Mechanisms of Activation and Regulation. Frontiers in Immunology, 2015, 6, 262. | 2.2 | 1,161 |
| 2 | Complement System Part II: Role in Immunity. Frontiers in Immunology, 2015, 6, 257. | 2.2 | 762 |
| 3 | Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International, 2012, 82, 454-464. | 2.6 | 454 |
| 4 | Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 2012, 8, 643-657. | 4.1 | 448 |
| 5 | Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. Journal of the American Society of Nephrology: JASN, 2010, 21, 859-867. | 3.0 | 383 |
| 6 | Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108. | 4.1 | 292 |
| 7 | Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort. PLoS Medicine, 2011, 8, e1001013. | 3.9 | 240 |
| 8 | Context-dependent roles of complement in cancer. Nature Reviews Cancer, 2019, 19, 698-715. | 12.8 | 217 |
| 9 | Complement factor H related proteins (CFHRs). Molecular Immunology, 2013, 56, 170-180. | 1.0 | 214 |
| 10 | Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood, 2013, 122, 282-292. | 0.6 | 207 |
| 11 | Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood, 2011, 117, 1340-1349. | 0.6 | 188 |
| 12 | C1q and its growing family. Immunobiology, 2007, 212, 253-266. | 0.8 | 174 |
| 13 | Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105. | 1.6 | 153 |
| 14 | Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845. | 0.6 | 140 |
| 15 | Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods, 2011, 365, 8-26. | 0.6 | 140 |
| 16 | Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight, 2018, 3, . | 2.3 | 135 |
| 17 | A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191. | 0.6 | 128 |
| 18 | Interaction of C1q with IgG1, C-reactive Protein and Pentraxin 3:Â Mutational Studies Using Recombinant Globular Head Modules of Human C1q A, B, and C Chainsâ€. Biochemistry, 2006, 45, 4093-4104. | 1.2 | 126 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Heme: Modulator of Plasma Systems in Hemolytic Diseases. Trends in Molecular Medicine, 2016, 22, 200-213. | 3.5 | 126 |
| 20 | Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood, 2015, 125, 2359-2369. | 0.6 | 112 |
| 21 | Complement Factor B Mutations in Atypical Hemolytic Uremic Syndromeâ€"Disease-Relevant or Benign?. Journal of the American Society of Nephrology: JASN, 2014, 25, 2053-2065. | 3.0 | 107 |
| 22 | Antibody Polyreactivity in Health and Disease: Statu Variabilis. Journal of Immunology, 2013, 191, 993-999. | 0.4 | 100 |
| 23 | Antiâ€"Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. Journal of Immunology, 2015, 194, 5129-5138. | 0.4 | 99 |
| 24 | Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 189, 3528-3537. | 0.4 | 96 |
| 25 | C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney International, 2017, 92, 1232-1241. | 2.6 | 93 |
| 26 | B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 91 |
| 27 | P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4/heme-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6280-6285. | 3.3 | 90 |
| 28 | Endothelial cells: source, barrier, and target of defensive mediators. Immunological Reviews, 2016, 274, 307-329. | 2.8 | 88 |
| 29 | Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2017, 28, 1603-1613. | 3.0 | 83 |
| 30 | Antibodies Use Heme as a Cofactor to Extend Their Pathogen Elimination Activity and to Acquire New Effector Functions. Journal of Biological Chemistry, 2007, 282, 26696-26706. | 1.6 | 81 |
| 31 | Mutational Analyses of the Recombinant Globular Regions of Human C1q A, B, and C Chains Suggest an Essential Role for Arginine and Histidine Residues in the C1q-IgG Interaction. Journal of Immunology, 2004, 172, 4351-4358. | 0.4 | 72 |
| 32 | Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome With CFH/CFHR1 Hybrid Protein. American Journal of Transplantation, 2012, 12, 1938-1944. | 2.6 | 70 |
| 33 | An Engineered Construct Combining Complement Regulatory and Surface-Recognition Domains Represents a Minimal-Size Functional Factor H. Journal of Immunology, 2013, 191, 912-921. | 0.4 | 70 |
| 34 | Loss of DGKÎµ induces endothelial cell activation and death independently of complement activation. Blood, 2015, 125, 1038-1046. | 0.6 | 69 |
| 35 | Functional and structural insight into properdin control of complement alternative pathway amplification. EMBO Journal, 2017, 36, 1084-1099. | 3.5 | 69 |
| 36 | The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood, 2014, 123, 121-125. | 0.6 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86. | 3.6 | 63 |
| 38 | Functional Complement C1q Abnormality Leads to Impaired Immune Complexes and Apoptotic Cell Clearance. Journal of Immunology, 2011, 187, 4369-4373. | 0.4 | 58 |
| 39 | Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 2020, 9, 57. | 1.2 | 58 |
| 40 | Heme Interacts with C1q and Inhibits the Classical Complement Pathway. Journal of Biological Chemistry, 2011, 286, 16459-16469. | 1.6 | 56 |
| 41 | Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins, 2019, 11, 660. | 1.5 | 55 |
| 42 | C1q+ macrophages: passengers or drivers of cancer progression. Trends in Cancer, 2022, 8, 517-526. | 3.8 | 51 |
| 43 | Anti-Factor B Antibodies and Acute Postinfectious GN in Children. Journal of the American Society of Nephrology: JASN, 2020, 31, 829-840. | 3.0 | 50 |
| 44 | Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis. Kidney International, 2021, 99, 581-597. | 2.6 | 48 |
| 45 | Role of Ca2+in the Electrostatic Stability and the Functional Activity of the Globular Domain of Human C1qâ€. Biochemistry, 2005, 44, 14097-14109. | 1.2 | 46 |
| 46 | Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. American Journal of Hematology, 2020, 95, 456-464. | 2.0 | 46 |
| 47 | Existence of Different but Overlapping IgG- and IgM-Binding Sites on the Globular Domain of Human C1qâ€. Biochemistry, 2006, 45, 9979-9988. | 1.2 | 45 |
| 48 | Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis. Journal of Biological Chemistry, 2015, 290, 25343-25355. | 1.6 | 44 |
| 49 | Heme induces human and mouse platelet activation through C-type-lectin-like receptor-2. Haematologica, 2021, 106, 626-629. | 1.7 | 44 |
| 50 | Coagulome and the tumor microenvironment: an actionable interplay. Trends in Cancer, 2022, 8, 369-383. | 3.8 | 44 |
| 51 | Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908. | 1.6 | 43 |
| 52 | Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260. | 2.2 | 42 |
| 53 | Atypical Hemolytic Uremic Syndrome Associated with Mutations in Complement Regulator Genes. Seminars in Thrombosis and Hemostasis, 2010, 36, 641-652. | 1.5 | 41 |
| 54 | Characterization of Renal Injury and Inflammation in an Experimental Model of Intravascular Hemolysis. Frontiers in Immunology, 2018, 9, 179. | 2.2 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1271-1276. | 1.1 | 40 |
| 56 | Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunology Research, 2021, 9, 909-925. | 1.6 | 40 |
| 57 | A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. Journal of the American Society of Nephrology: JASN, 2016, 27, 1665-1677. | 3.0 | 39 |
| 58 | Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus antiâ€C1q antibodies by a specific peptideâ€based enzymeâ€linked immunosorbent assay. Arthritis and Rheumatism, 2012, 64, 3706-3714. | 6.7 | 37 |
| 59 | Heme Drives Susceptibility of Glomerular Endothelium to Complement Overactivation Due to Inefficient Upregulation of Heme Oxygenase-1. Frontiers in Immunology, 2018, 9, 3008. | 2.2 | 36 |
| 60 | A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney International, 2017, 92, 876-887. | 2.6 | 35 |
| 61 | Iron Ions and Haeme Modulate the Binding Properties of Complement Subcomponent C1q and of Immunoglobulins. Scandinavian Journal of Immunology, 2007, 65, 230-239. | 1.3 | 32 |
| 62 | Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Transfusion Clinique Et Biologique, 2019, 26, 116-124. | 0.2 | 32 |
| 63 | Complement C1qâ€target proteins recognition is inhibited by electric moment effectors. Journal of Molecular Recognition, 2007, 20, 405-415. | 1.1 | 29 |
| 64 | Genetics of hemolytic uremic syndromes. Presse Medicale, 2012, 41, e105-e114. | 0.8 | 28 |
| 65 | Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. Nephrology Dialysis Transplantation, 2013, 28, 2899-2907. | 0.4 | 25 |
| 66 | Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling. Journal of Immunology, 2016, 197, 3669-3679. | 0.4 | 25 |
| 67 | Analysis of protein missense alterations by combining sequenceâ€and structureâ€based methods. Molecular Genetics & Genomic Medicine, 2020, 8, e1166. | 0.6 | 25 |
| 68 | Intravenous Immunoglobulin with Enhanced Polyspecificity Improves Survival in Experimental Sepsis and Aseptic Systemic Inflammatory Response Syndromes. Molecular Medicine, 2015, 21, 1002-1010. | 1.9 | 24 |
| 69 | Hemopexin as an Inhibitor of Hemolysis-Induced Complement Activation. Frontiers in Immunology, 2020, 11, 1684. | 2.2 | 24 |
| 70 | Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Frontiers in Immunology, 2021, 12, 680567. | 2.2 | 24 |
| 71 | Autoantibodies Against C3bâ€”Functional Consequences and Disease Relevance. Frontiers in Immunology, 2019, 10, 64. | 2.2 | 22 |
| 72 | Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Antiâ€“Factor H IgAÎ» Antibody. American Journal of Kidney Diseases, 2015, 66, 331-336. | 2.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Site-specific N-glycosylation analysis of soluble FcÎ³ receptor IIIb in human serum. Scientific Reports, 2018, 8, 2719. | 1.6 | 21 |
| 74 | Heme Oxygenase 1: A Defensive Mediator in Kidney Diseases. International Journal of Molecular Sciences, 2021, 22, 2009. | 1.8 | 19 |
| 75 | Complement C3 is a novel modulator of the anti-factor VIII immune response. Haematologica, 2018, 103, 351-360. | 1.7 | 17 |
| 76 | The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction. Transfusion Medicine Reviews, 2019, 33, 225-230. | 0.9 | 16 |
| 77 | The receptor for advanced glycation end products is a sensor for cellâ€free heme. FEBS Journal, 2021, 288, 3448-3464. | 2.2 | 16 |
| 78 | Functional Evaluation of Factor H genetic and Acquired Abnormalities: Application for Atypical Hemolytic Uremic Syndrome (aHUS). Methods in Molecular Biology, 2014, 1100, 237-247. | 0.4 | 15 |
| 79 | A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. Journal of Thrombosis and Haemostasis, 2010, 8, 1524-1531. | 1.9 | 13 |
| 80 | Mechanism and Functional Implications of the Heme-Induced Binding Promiscuity of IgE. Biochemistry, 2015, 54, 2061-2072. | 1.2 | 13 |
| 81 | Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 690821. | 2.2 | 13 |
| 82 | Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. American Journal of Obstetrics and Gynecology, 2021, 225, 662.e1-662.e11. | 0.7 | 13 |
| 83 | Anti-Factor H Autoantibodies Assay. Methods in Molecular Biology, 2014, 1100, 249-256. | 0.4 | 12 |
| 84 | Physiological and therapeutic complement regulators in kidney transplantation. Current Opinion in Organ Transplantation, 2013, 18, 421-429. | 0.8 | 11 |
| 85 | Heme-Exposed Pooled Therapeutic IgG Improves Endotoxemia Survival. Inflammation, 2017, 40, 117-122. | 1.7 | 9 |
| 86 | B cells and complement at the forefront of chemotherapy. Nature Reviews Clinical Oncology, 2020, 17, 393-394. | 12.5 | 9 |
| 87 | Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside. Frontiers in Immunology, 2022, 13, 860689. | 2.2 | 9 |
| 88 | Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme. Molecular Immunology, 2019, 111, 205-208. | 1.0 | 8 |
| 89 | Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. Frontiers in Immunology, 2020, 11, 1772. | 2.2 | 8 |
| 90 | A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein. Frontiers in Immunology, 2018, 9, 2822. | 2.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. Molecular Immunology, 2009, 47, 290-297. | 1.0 | 6 |
| 92 | Plasma C3d levels as a diagnostic marker for complete complement factor I deficiency. Journal of Allergy and Clinical Immunology, 2021, 147, 749-753.e2. | 1.5 | 6 |
| 93 | Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. Methods in Molecular Biology, 2021, 2227, 191-203. | 0.4 | 5 |
| 94 | Hemolytic uremic syndrome associated with Bordetella pertussis infection in a 2-month-old infant carrying a pathogenic variant in complement factor H. Pediatric Nephrology, 2019, 34, 533-537. | 0.9 | 4 |
| 95 | Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology. Methods in Molecular Biology, 2019, 1901, 271-280. | 0.4 | 4 |
| 96 | Clinical and functional consequences of antiâ€properdin autoantibodies in patients with lupus nephritis. Clinical and Experimental Immunology, 2020, 201, 135-144. | 1.1 | 4 |
| 97 | Glomerulonephritis With Isolated C3 Deposits as a Manifestation of Subtotal Factor I Deficiency. Kidney International Reports, 2019, 4, 1354-1358. | 0.4 | 3 |
| 98 | Heme: driver of erythrocyte elimination. Blood, 2021, 138, 1092-1094. | 0.6 | 3 |
| 99 | 1st EFIS-EJI Intensive Course in Clinical Immunology: Towards a new era in Immunology. European Journal of Immunology, 2011, 41, 268-269. | 1.6 | 2 |
| 100 | Exploration du complÃ©ment : actualitÃ©s 2012. Revue Francophone Des Laboratoires, 2012, 2012, 31-37. | 0.0 | 2 |
| 101 | The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20. | 0.4 | 2 |
| 102 | Complement factor H: a guardian within?. Kidney International, 2021, 100, 747-749. | 2.6 | 2 |
| 103 | Terminal complement without C5 convertase?. Blood, 2021, 137, 431-432. | 0.6 | 2 |
| 104 | A role for complement blockade in kidney transplantation. , 2022, , . | | 2 |
| 105 | C3dg-CR3 interaction in erythrophagocytosis. Blood, 2015, 126, 828-829. | 0.6 | 1 |
| 106 | Detection of Anti-C3b Autoantibodies by ELISA. Methods in Molecular Biology, 2021, 2227, 133-139. | 0.4 | 1 |
| 107 | Complement C3 Deposition on Endothelial Cells Revealed by Flow Cytometry. Methods in Molecular Biology, 2021, 2227, 97-105. | 0.4 | 1 |
| 108 | Ex Vivo Complement Activation on Endothelial Cells: Research and Translational Value. Trends in Molecular Medicine, 2021, 27, 418-421. | 3.5 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Registration of the Interaction Between C1q Human Complement Derivatives and Immunoglobulins by Elisaâ€"Role of the Solid Phase. Biotechnology and Biotechnological Equipment, 2004, 18, 116-120. | 0.5 | 0 |
| 110 | Contribution of the C1q Polypeptide Chains in the Recognition of CRP. Biotechnology and Biotechnological Equipment, 2005, 19, 122-125. | 0.5 | 0 |
| 111 | Intravascular hemolysis induces complement system activation. Molecular Immunology, 2017, 89, 164. | 1.0 | 0 |
| 112 | Atypical hemolytic uremic syndrome â€" Why the kidney?. Molecular Immunology, 2017, 89, 172-173. | 1.0 | 0 |
| 113 | FP076ATYPICAL HEMOLYTIC UREMIC SYNDROME - WHY THE KIDNEY?. Nephrology Dialysis Transplantation, 2018, 33, i74-i74. | 0.4 | 0 |
| 114 | Intratumoral classical complement pathway promotes tumor growth in renal cancer. Molecular Immunology, 2018, 102, 205. | 1.0 | 0 |
| 115 | LBA29 COMPLEMENT ACTIVATION ORCHESTRATED BY CANCER CELLS AND C1Q-PRODUCING TUMOR ASSOCIATED MACROPHAGES HAS A DELETERIOUS IMPACT ON PATIENTâ€™S PROGNOSIS IN CLEAR CELL RENAL CELL CANCER.. Journal of Urology, 2018, 199, . | 0.2 | 0 |
| 116 | ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A Â«KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMESÂ» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39. | 0.1 | 0 |
| 117 | Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , . | | 0 |
| 118 | Abstract 2334: Intratumoral classical complement pathway promotes tumor growth in renal cancer. , 2019, , . | | 0 |